Pathological Stage T2 Subgroups to Predict Biochemical Recurrence After Prostatectomy
Yakup Kordan(Vanderbilt University Medical Center), Daniel A. Barocas(Vanderbilt University Medical Center), Michael S. Cookson(University of Oklahoma Health Sciences Center), S. Duke Herrell(Vanderbilt University Medical Center), Peter E. Clark(Levine Cancer Institute), Sharon Phillips(Vanderbilt University Medical Center), Joseph A. Smith(King's College London), Sam S. Chang(Vanderbilt University), Rodney Davis(The University of Texas MD Anderson Cancer Center), Roxelyn G. Baumgartner(Vanderbilt University Medical Center), Shady Salem(Vanderbilt University Medical Center)
Cited by 49
Related Papers
The Long-Term Effect of Doxazosin, Finasteride, and Combination Therapy on the Clinical Progression of Benign Prostatic Hyperplasia
|New England Journal of Medicine|2003|2k
Guideline for the Management of Clinically Localized Prostate Cancer: 2007 Update
|The Journal of Urology|2007|1.1k
Variation in the Definition of Biochemical Recurrence in Patients Treated for Localized Prostate Cancer: The American Urological Association Prostate Guidelines for Localized Prostate Cancer Update Panel Report and Recommendations for a Standard in the Reporting of Surgical Outcomes
|The Journal of Urology|2007|845
Robot-assisted radical cystectomy versus open radical cystectomy in patients with bladder cancer (RAZOR): an open-label, randomised, phase 3, non-inferiority trial
|The Lancet|2018|779
Prostate Cancer, Version 4.2023, NCCN Clinical Practice Guidelines in Oncology
|Journal of the National Comprehensive Cancer Network|2023|592